Sonnet BioTherapeutics Holdings, Inc. short interest in 2025
In 2025, Sonnet BioTherapeutics Holdings, Inc.'s disclosed short interest ran from 2.11% of shares outstanding on 15 Jan 2025 to 27.70% on 28 Nov 2025, a change of +25.59 percentage points. The year's high was 37.44% on 31 Oct 2025 and its low 1.30% on 30 Jun 2025, averaging 14.22% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 5.89 days on 29 Aug 2025. Full history: Sonnet BioTherapeutics Holdings, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025
2025 in figures
- Start of year
- 2.11% (15 Jan 2025)
- End of year
- 27.70% (28 Nov 2025)
- Change
- +25.59 pp
- High
- 37.44% (31 Oct 2025)
- Low
- 1.30% (30 Jun 2025)
- Average
- 14.22%
- Highest days to cover
- 5.89 (29 Aug 2025)
- SEC filings marked
- 5
Every report in 2025
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2025 | 2.11% | 1.00 | |
| 31 Jan 2025 | 3.84% | 1.00 | |
| 14 Feb 2025 | 2.65% | 1.54 | 10-Q filed, results (8-K) |
| 28 Feb 2025 | 3.09% | 1.00 | |
| 14 Mar 2025 | 1.71% | 1.52 | |
| 31 Mar 2025 | 3.78% | 2.53 | |
| 15 Apr 2025 | 5.47% | 3.20 | |
| 30 Apr 2025 | 4.13% | 2.76 | |
| 15 May 2025 | 3.10% | 3.93 | 10-Q filed |
| 30 May 2025 | 1.51% | 1.05 | |
| 13 Jun 2025 | 1.92% | 1.78 | |
| 30 Jun 2025 | 1.30% | 1.00 | |
| 15 Aug 2025 | 27.77% | 1.92 | 10-Q filed |
| 29 Aug 2025 | 27.63% | 5.89 | |
| 15 Sep 2025 | 33.10% | 1.40 | |
| 30 Sep 2025 | 31.90% | 1.41 | |
| 15 Oct 2025 | 32.35% | 4.52 | |
| 31 Oct 2025 | 37.44% | 4.78 | |
| 14 Nov 2025 | 31.85% | 2.56 | |
| 28 Nov 2025 | 27.70% | 2.61 |
See also: Sonnet BioTherapeutics Holdings, Inc.'s full history · most shorted US stocks of 2025 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.